Search Results for "HCV"

Dr. Peter Bach, alongside Kathy Sego, Dr. Douglas Holtz-Eakin, and Dr. Mark Miller, testified before U.S. Senate Finance Committee at its first hearing of the session, Drug Pricing in America: A Prescription for Change, Part I.

An overview of the original subscription-based Netflix model proposed and the proposals put forth by Louisiana and Washington.

An alternative payment model is proposed to support a population-level payment paradigm.

Drug Pricing Lab op-ed in STAT News discusses indication-specific pricing of Kymriah.

At $500 per pill, buying Gilead could lower hepatitis C drug costs per patient to one-third their current level, making it affordable to rapidly treat the 2.7 million Americans that have HCV.